Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

$3.35 $3.09

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 67,855 66,398

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 75,580 78,814

Notes to Reconciliation of GAAP Net Income to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets ($77.0 million in 2008; $64.2 million in 2007), accelerated depreciation related to the CIMA LABS restructuring ($5.4 million in 2008), accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($2.9 million in 2008), and the write-off of purchase commitments in excess of estimated requirements ($26.0 million in 2008).

(2) To exclude charges related to payments for several research and development collaborations ($6.0 million in 2008; $26.5 million in 2007), other charges related to employee severance costs ($1.8 million in 2008), and accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($0.3 million in 2008). In 2007, we also excluded the recognition of a milestone ($15.0 million) related to the FDA's acceptance of our NDA filing for TREANDA.

(3) To exclude charges related to employee severance costs ($3.0 million) and charges related to the estimated termination payments due to Takeda Pharmaceuticals North America, Inc. ($27.2 million).

(4) In 2008, to exclude charges related to the settlement of investigations by the Offices of the Attorney General of Connecticut and Massachusetts and estimated relator attorney fees. In 2007, to exclude the reserve established for the minimum liability related to the potential settlement of the investigations by the U.S. Attorney's Office.

(5) To exclude the pre-tax gain related to the sale of certain investments.

(6) To exclude the forgiveness of a mortgage loan by the PIDA.

(7) To exclude the accrued int
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 30, 2015 Sanofi, ... for the second quarter of 2015. CEO ... and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in ... - Performance drivers - ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), one ... services, offering both facility-based and home-based post-acute services, ... second quarter ended June 30, 2015. ... growth in both segments and an 11.0% increase ... and Chief Executive Officer of HealthSouth. "While reported ...
(Date:7/29/2015)... 29, 2015 Research ... addition of the "Global Biosimilars Market, 2015 ... The Global Biosimilars Market, 2015 - 2025, ... growing biosimilars market. With the blockbuster biologics losing ... costs, biosimilars are being viewed as viable substitutes ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27
... Nov. 20 MDV-Mohr Davidow Ventures, a,leading Silicon ... of,Phyllis Whiteley and Dan Riskin to the firm ... develop start-up,opportunities that provide healthcare providers and consumers ... from prevention to diagnosis to the,treatment of disease. ...
... China Medical Technologies, Inc.,(the "Company") (Nasdaq: ... develops, manufactures and markets advanced in-vitro diagnostic products,today ... of two,proprietary molecular diagnostic kits for the detection ... with non-small cell lung,cancer ("NSCLC"). The Company expects ...
... popular family Web sites, today announced a partnership ... for genealogic research. In addition to MyHeritage,s innovative ... also use information contained in their DNA to ... from many hundreds of years ago. FamilyTreeDNA users ...
Cached Biology Technology:MDV Expands Team Pursuing Advances in Personalized Medicine 2China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits 2MyHeritage And Family Tree DNA Partner To Help People Trace Family History Using DNA 2MyHeritage And Family Tree DNA Partner To Help People Trace Family History Using DNA 3MyHeritage And Family Tree DNA Partner To Help People Trace Family History Using DNA 4
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading ... for its second quarter ended June 30, 2015.  ... million, a decrease of 33% compared to $6.8 million in ... quarter of 2015 was $0.3 million, or $0.01 per diluted ... share, in the same period a year ago.  ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... at the University of Chicago finds evidence for a ... of loneliness: They create people in their surroundings to ... very efficient way to alleviate ones loneliness, but you ... so, said Nicholas Epley, Assistant Professor of Behavioral Science ...
... French . Researchers at the ... neurological basis of depression in male athletes with persisting ... of Archives of General Psychiatry, has important clinical implications ... cerebral concussion. Depression is one of a ...
... German . Genetically engineered products have become ... future, gene therapy should make it possible to introduce genes ... can address deficiencies to compensate for malfunctions in the body. ... must be introduced into host cells, which is not exactly ...
Cached Biology News:People not always needed to alleviate loneliness 2People not always needed to alleviate loneliness 3MNI researchers locate neurological basis of depression following sports concussion 2Cells get sprayed 2